Loading
Sentiment · FY2026 Q2
| Analyst | Firm | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Larry Biegelsen | Wells Fargo | 14 (21%) |
| Vijay Kumar | Evercore ISI | 14 (21%) |
| Travis Steed | Bank of America | 14 (14%) |
| Robbie Marcus | JPMorgan | 13 (8%) |
| David Roman | Goldman Sachs | 12 (8%) |
| Matt Taylor | Jefferies | 7 (0%) |
| Joanne Wuensch | Citigroup | 5 (0%) |
| Matt Miksic | Barclays | 5 (0%) |
| Pito Chickering | Deutsche Bank | 5 (0%) |
| Chris Pasquale | Nephron Research | 3 (33%) |
| Firm | Analysts | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Bank of America | 1 | 14 (14%) |
| Evercore ISI | 1 | 14 (21%) |
| Wells Fargo | 1 | 14 (21%) |
| JPMorgan | 1 |
| 13 (8%) |
| Goldman Sachs | 1 | 12 (8%) |
| Jefferies | 1 | 7 (0%) |
| Deutsche Bank | 1 | 5 (0%) |
| Barclays | 1 | 5 (0%) |
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $1.39B | +9.4% | $0.65 | +6.6% | 78.9% | 22.6% | 27.8% | $-177M |
| FY2025 Q1 | $1.41B | +6.2% | $0.61 | +5.2% | 78.7% | 27.9% | 25.3% | $224M |
| FY2025 Q2 | $1.53B | +10.6% | $0.56 | -8.2% | 77.6% | 28.1% | 21.5% | $241M |
| FY2025 Q3 | $1.55B | +14.7% | $0.50 | -90.3% | 77.9% | 27.4% | 18.7% | $516M |
| FY2025 Q4 | $1.57B | +13.3% | $0.16 | -75.4% | 78.3% | 23.6% | 5.8% | $354M |
| FY2026 Q1 | $1.65B | +16.7% | $0.66 | +8.2% | 78.2% | 31.2% | 23.1% | $-21M |
| FY2026 Q2 | $1.74B | +13.6% | $0.42 | -25.0% | 77.6% | 29.8% | 13.9% | — |
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
Edwards Lifesciences opened FY2026 with reported sales of $1.65 billion, up 12.7% on an underlying basis (about 16.7% as reported, aided by roughly 400 basis points of favorable foreign exchange), with broad-based strength across TAVR, TMTT, and Surgical. TAVR sales rose 11% to $1.2 billion on renewed clinical focus and long-term SAPIEN durability evidence, while TMTT surged approximately 42% to $173 million on EVOQUE, PASCAL, and the new SAPIEN M3. Adjusted EPS of $0.78 beat expectations and adjusted operating profit margin reached 31.4%, reflecting operating leverage and planned phasing of strategic investments, while GAAP EPS was $0.66. On the back of the Q1 outperformance, management raised full-year sales-growth guidance to 9%-11% and adjusted EPS guidance to $2.95-$3.05, and pointed to potential reimbursement tailwinds from the CMS TAVR NCD reconsideration and the new RAPID breakthrough-therapy policy.
Demand | Innovation & R&D | Product Launch | Competitive Dynamics | Revenue Growth | Regulation Policy | Guidance Reliability | Margin | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 7 | 4 | 9 | 1 | 7 | 2 | 4 | 1 |
| 2025Q1 | 7 | 4 | 5 | 4 | 4 | 6 | 2 | 3 |
| 2025Q2 | 6 | 3 | 3 | 4 | 1 | 3 | 4 | 5 |
| 2025Q3 | 6 | 6 | 2 | 2 | 1 | 2 | 1 | 3 |
| 2025Q4 | 6 | 5 | 2 | 3 | 4 | 2 | 1 | 1 |
| 2026Q1 | 2 | 3 | 3 | 6 | 1 | 2 | 3 | 1 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Demand | 7 | 7 | 6 | 6 | 6 | 2 |
| Innovation & R&D | 4 | 4 | 3 | 6 | 5 | 3 |
| Product Launch | 9 | 5 | 3 | 2 | 2 | 3 |
| Competitive Dynamics | 1 | 4 | 4 | 2 | 3 | 6 |
| Revenue Growth | 7 | 4 | 1 | 1 | 4 | 1 |
| Regulation Policy | 2 | 6 | 3 | 2 | 2 | 2 |
| Guidance Reliability | 4 | 2 | 4 | 1 | 1 | 3 |
| Margin | 1 | 3 | 5 | 3 | 1 | 1 |
What EW and other companies said about each other on FY2026 Q1 earnings calls — extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“And similar to the Edwards trials, there was some late catch-up in mortality.”
An analyst compares Medtronic CoreValve long-term mortality data to Edwards Lifesciences' TAVR trial results.
“on David's question on the Evolut 6- and seven-year data. It was obviously the big news in the quarter.”
Analysts pressed Edwards on the long-term Evolut durability data (Medtronic's competing TAVR valve), the quarter's key competitive event; Edwards indicated it benefited from slight share gains in the wake of that data.
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
EW Edwards Lifesciences | 9 | +16.7% | |
| ABT Abbott Laboratories | 6 | +7.8% | |
| ALGN Align Technology | 6 | +6.2% | |
| BSX Boston Scientific | 6 | +11.6% | |
| DXCM DexCom | 9 | +15.1% | |
| MDT Medtronic | 7 | +8.8% | |
| PODD Insulet Corporation | 8 | +33.9% | |
| STE Steris | 7 | +7.3% | |
| SYK Stryker Corporation | 4 | +2.6% | |
| ZBH Zimmer Biomet | 9 | +9.3% |